Skip to main content
Home
Latest news
Browse topics
Lupus Rheumatoid arthritis Spondyloarthropathies COVID-19 Browse all topics
In focus
Bimekizumab: Dual IL-17A/IL-17F inhibition in SpA Anifrolumab for the treatment of SLE JAK inhibitor safety: Weighing up the data and understanding the risks Rituximab and rheumatology practice in the COVID-19 era Safety snapshot: Upadacitinib in patients with PsA Repurposing rheumatology drugs for COVID-19 Telemedicine in rheumatology: COVID-19 and beyond Managing PsA in resource-limited settings
Conferences
ACR Convergence 2022 EULAR 2022 Congress
About us
Medicine Matters Rheumatology
EXTENDED SEARCH
Top

12-11-2019 | Ankylosing spondylitis | Video | Article

ACR/ARP 2019

Researcher comment: The SELECT-AXIS 1 trial

print
PRINT
insite
SEARCH

Désirée van der Heijde discusses the results of SELECT-AXIS 1, a phase II/III trial demonstrating that upadacitinib may be a promising treatment option for ankylosing spondylitis (2:27).

External Content

Click Play to display this content and agree to third party cookies. (>)

Update your current cookie settings.

Transcript

Back to the ACR/ARP 2019 conference hub

print
PRINT

Related content

12-11-2019 | Ankylosing spondylitis | ACR/ARP 2019 | News

Upadacitinib demonstrates potential for ankylosing spondylitis

21-02-2019 | Spondyloarthropathies | Feature | Article

Trials of JAK inhibitors in spondyloarthritis: A round-up

23-08-2019 | Axial spondyloarthritis | News

US guidelines for the treatment of axSpA published
Image Credits